Yes, We're Still Crazy About Biotech

It's a tale of two sectors. First, find out why we're still crazy about biotech...

You are receiving this email because you signed up to receive our free e-letter, or you purchased a product or service from its publisher, The Oxford Club. If you are having trouble viewing this email, click here to view it in your browser. IU Plus | Courses | Conference | IU Bookstore Wednesday, August 31, 2016 | Issue #2879 New Video Shows How To Play The 2016 Presidential Election No matter which horse you have in this race, America could be in big trouble... Do nothing and your retirement-everything you've worked for so far-may be in jeopardy... But take heart... if you follow our lead, this election may just be the best thing that's ever happened to you... This new video shows how. SPONSORED A Tale of Two Sectors Alexander Moschina, Managing Editor, Investment U At first glance, the performance of healthcare and commodities could not seem more different. One's gotten crushed in 2016... And the other's been crushing. Here's the year-to-date performance of healthcare as tracked by the Healthcare Select Sector SPDR ETF (NYSE: XLV) vs. the SPDR Gold Shares ETF (NYSE: GLD), the SPDR Global Natural Resources ETF (NYSE: GNR) and the S&P 500. As you can see, healthcare stocks - on the whole - have just barely made it into the black this year. Meanwhile, commodities are up more than 20%. And even the broad market is beating healthcare by fivefold. Still, as with most things in life, there's a whole lot more to this story... Longtime readers know that we're true contrarians at heart. (Matthew Carr reaffirmed this status in his column yesterday.) So when a sector takes a dive, that's when we pick up the magnifying glass. Today's issue is a tale of two sectors. First, find out why we're still crazy (yes, even after all this volatility) about biotech... And later, hear what Sean Brodrick, Resource Strategist at The Oxford Club, has to say about the near-term future of gold and oil prices. Good investing, Alexander There's Good News in Biotech Stocks... If You Know Where to Look Samuel Taube, Investment U Research Team It's been a bumpy year for biotech stocks. Industry index funds are down by double digits. The main culprit? A rash of bad PR. 2016 has seen a number of scandals and botched clinical trials from big names like Theranos and Valeant (NYSE: VRX). Most recently, Mylan (Nasdaq: MYL) made headlines when it hiked EpiPen prices by 400%... while at the same time raising salaries for top executives. These negative stories have put the healthcare market in a sour mood. But believe it or not, there's still plenty of upside in the sector. You just have to know where to look. In truth, biotechnology isn't a single industry. It's made up of several distinct fields of medical research and development. Most of the pessimism is centered on the field of treatment drugs. But many other areas, like genomics, surgical tech and vaccines, have been doing just fine. We're going to look at some biotech stocks that aren't focused on the more volatile pill-making industry. These three companies have actually seen double-digit gains over the course of this year... [Read the rest on InvestmentU.com] John D. Rockefeller-Founded Company Still Paying Out $583 Million to a Few Lucky Shareholders... The payments have increased every year on record. We think it'll top $600 million by early next year... $700 million by 2019... and soon over $1 billion annually. Here's why you never heard about it... until now. Oxford Club Radio: The Current State of Commodities (With Sean Brodrick) Investment U Research Team On this week's episode of Oxford Club Radio, Marc interviews gold and commodities expert Sean Brodrick. The two discuss current trends in precious metals, oil and more. Also in the spotlight this week? Two notoriously opaque organizations - the Federal Reserve and OPEC. Click "play" above to watch the first half of Marc's chat with Sean - or read on for our brief recap of what's happening in commodities markets... [Read the rest on InvestmentU.com] Will You Buy Any "Big-Ticket Items" in 2016? A new car... big vacation... engagement ring... fishing boat... college tuition payments... repairs to your home? If so, the government may owe you money. A new law signed at the end of 2015 offers "cash rebates" to 119 million eligible Americans for purchases made in 2016. This is a chance to collect anywhere from $1,230 up to $12,900 and perhaps beyond. But you must prepare now to maximize your payout. Details "here. We Also Recommend... Global Markets and Currency Trends Briefing by Investment U Research Team Tuesday, August 30, 2016 Last week was eventful for macro-savvy investors. Learn why in this week's Global Markets and Currency Trends Briefing. Read On... A Simple Way to Profit in the New Era of Investing by Matthew Carr Tuesday, August 30, 2016 In recent years, we've entered a new era in terms of how the market performs. Here's a simple way to adapt and achieve true success as an investor. Read On... Why I'm Bullish on "The Robot Revolution" by Alexander Green Monday, August 29, 2016 The gloom-and-doomers are warning of the coming "Robot Revolution." Here's why investors shouldn't be quaking in their boots. Read On... You are receiving this email because you subscribed to Investment U. To unsubscribe from Investment U, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Investment U | Attn: Member Services | 105 West Monument Street | Baltimore, MD 21201 North America: 1.855.402.3939 | International: +1.443.353.4057 | Fax: 1.410.329.1923 Website: www.investmentu.com Keep the emails you value from falling into your spam folder. Whitelist Investment U. © 2016 The Oxford Club LLC All Rights Reserved The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.